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Abstract
Upper non-variceal gastrointestinal bleeding is a condition 
that requires immediate medical intervention and has 
a high associated mortality rate (exceeding 10%). The 
vast majority of upper gastrointestinal bleeding cases 
are due to peptic ulcers. Helicobacter pylori  infection, 
non-steroidal anti-inflammatory drugs and aspirin are 
the main risk factors for peptic ulcer disease. Endoscopic 
therapy has generally been recommended as the first-
line treatment for upper gastrointestinal bleeding as 
it has been shown to reduce recurrent bleeding, the 
need for surgery and mortality. Early endoscopy (within 
24 h of hospital admission) has a greater impact than 
delayed endoscopy on the length of hospital stay and 
requirement for blood transfusion. This paper aims 
to review and compare the efficacy of the types of 
endoscopic hemostasis most commonly used to control 
non-variceal gastrointestinal bleeding by pooling data 
from the literature. 
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Core tip: Review and comparison the efficacy of the 
most commonly used types of endoscopic hemostasis 
for the control of non-variceal gastrointestinal bleeding 
in clinical practice by pooling data from the literature.
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INTRODUCTION
Acute upper gastrointestinal bleeding (UGIB) is a 
common medical entity for which endoscopy has become 
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the primary diagnostic and therapeutic technique. 
Endoscopy performed in patients with UGIB corresponds 
with a reduction in required blood transfusions and 
length of intensive care unit/total hospital stay[1]. Upper 
endoscopy is required for most patients with UGIB and 
should be performed within 24 h of hospital admission 
after adequate prior fluid resuscitation[2]. The key to 
improving outcomes is the proper initial management 
of individuals who present with UGIB. In most clinical 
conditions, the vast majority (80%-90%) of episodes 
of acute upper gastrointestinal bleeding are secondary 
to non-variceal origin. This review addresses different 
endoscopic techniques of hemostasis that are used 
to treat acute upper gastrointestinal bleeding of non-
variceal origin (NVUGIB) in the world practice.
EPIDEMIOLOGY
UGIB is mostly non-variceal in origin and still remains 
one of the most common challenges encountered by 
surgeons, gastroenterologists and endoscopists in a 
daily clinical setting. The incidence rate of non-variceal 
UGIB ranges from 50 to 150 per 100000 adults/year[3]. 
In spite of major advances in the approaches used to 
manage non-variceal UGIB over the past 2 decades, 
including the peptic ulcer bleeding prevention, the 
optimal use of endoscopic therapy, as well as the use 
of adjuvant high-dose proton pump inhibitors (PPIs) to 
eradicate Helicobacter pylori, it is still associated with 
considerable morbidity, mortality, and health care costs. 
The most common non-variceal bleeding etiologies 
include gastroduodenal peptic ulcer (20%-50%), gastro-
duodenal erosions (8%-15%), Mallory-Weiss tears 
(8%-15%), erosive esophagitis (5%-15%), arterio-
venous malformations/GAVE (5%); several other 
conditions [e.g., Dieulafoy’s lesion, upper gastrointes-
tinal (GI) tract malignancy] make up the remaining 
causes[4-7]. Peptic ulcer disease still remains the most 
common cause of acute NVUGIB and accounts for at 
least 50% of cases. Ulcers with signs of active spurting 
(Forrest class ⅠA) or oozing blood (Forrest class ⅠB) 
and ulcers with a nonbleeding visible vessel (Forrest 
ⅡA) are at high risk of recurrent bleeding when only 
medical therapy is used. Thus, endoscopic hemostasis is 
required for patients with high-risk stigmata [ⅠA, ⅠB] 
or a visible vessel in an ulcer niche [ⅡA]. Clean-based 
ulcers (Forrest class Ⅲ) or flat pigmented spots in the 
ulcer bed (Forrest class ⅡC) are low-risk lesions that 
only rebleed in 4% to 13% of cases and can therefore 
be treated with pharmacotherapy alone and considered 
for outpatient management[8,9]. Ulcers with adherent 
clots (Forrest class ⅡB) have an intermediate risk of 
rebleeding (approximately 25%) that depends on the 
underlying lesion. For that reason, clot removal should 
be performed with vigorous irrigation and manipulation 
with an endoscope, forceps, or snare. In patients suffer-
ing from peptic ulcer disease, duodenal ulcer bleeding 
appears more frequently than from gastric ulcers[10]. A 
Blatchford score or pre-endoscopic Rockall score (based 
on age, comorbidity, and the presence or absence of 
hemodynamic instability) should be used to stratify 
risk and determine which patients require prompt 
endoscopy or, conversely, to determine suitability 
for early discharge (Table 1). The Blatchford score, a 
validated risk-stratification tool based solely on clinical 
and laboratory variables, is used to predict the need for 
endoscopic intervention in patients with acute upper GI 
hemorrhage. A higher score indicates a higher likelihood 
of needing endoscopic intervention (score ranges from 0 
to 23). The clinical Rockall score (i.e., the score obtained 
before endoscopy is performed) is calculated solely 
on the basis of clinical variables at the time of patient 
presentation. The complete Rockall score makes use of 
both clinical and endoscopic criteria to assess patient risk 
of re-bleeding and mortality. Rockall score ranges from 
0 to 11 points, with higher scores indicating a higher risk 
for a poor outcome (Table 2)[11,12].
ENDOSCOPIC MANAGEMENT
The aim of therapeutic endoscopy is to stop any 
ongoing bleeding and to prevent rebleeding. Cooper et 
al[13] studied the effectiveness of performing an early 
endoscopy within the first 24 h of an acute UGIB episode 
and found it to be associated with reductions in the 
length of hospital stay, the rate of recurrent bleeding, 
and the need for emergent surgical intervention. Accord-
ing to the 2010 international consensus on non-variceal 
upper gastrointestinal bleeding, early endoscopy (within 
24 h of presentation) is appropriate for most patients 
with UGIB[2]. In cases of rebleeding, a second attempt 
at endoscopic therapy is recommended to reduce the 
need for surgery. In patients who have undergone failed 
endoscopic therapy, surgery should be considered. 
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Table 1  Blatchford scoring: Admission risk markers and 
associated score component values[13]
Admission risk marker Score component value
Blood urea, mmol/L
6.5 to ≤ 8 2
8.0 to < 10.0 3
10.0 to < 25 4
≥ 25 6
Hemoglobin for men, g/dL
12.0-13.0 1
10.0 to < 12.0 3
< 10.0 6
Hemoglobin for women, g/dL
10.0 to < 12.0 1
10 6
Systolic blood pressure, mmHg
100-109 1
90-99 2
< 90 3
Other markers
Pulse ≥ 100/min 1
Presentation with melena 1
Presentation with syncope 2
Hepatic disease 2
Cardiac failure 2
Despite adequate initial endoscopic therapy, recurrent 
UGIB can occur in up to 24% of high-risk patients. The 
use of PPI therapy in addition to endoscopic therapy 
reduces the rate of recurrent bleeding to approximately 
10%. Patients with recurrent bleeding generally respond 
favorably to repeated endoscopic therapy. Routine 
second-look endoscopy, defined as a planned endoscopy 
performed within 24 h of the initial endoscopy, is not 
recommended. In cases where the initial endoscopy 
failed to identify the source (e.g., because of a large clot 
in the stomach) or if there are concerns that inadequate 
therapy was delivered, second-look endoscopy may be 
appropriate (Table 3).
Currently, the efficacy and safety of endoscopic 
hemostasis rely on the identification of lesions that are 
suitable for endoscopic therapy, the selection of the 
appropriate hemostatic devices, attention to technique, 
and prompt recognition and management of procedure-
related adverse events. The suitable technique should 
be chosen based on the appearance of the bleeding 
focus and the related risk for persistent or recurrent 
bleeding. 
The traditional endoscopic modalities are injection, 
mechanical therapy, and thermal approaches. Injection 
agents include saline, dilute epinephrine, sclerosing 
agents (ethanolamine, polidocanol, absolute alcohol, 
and sodium tetradecyl sulfate), and tissue adhesives 
(cyanoacrylate, thrombin, and fibrin glue). Mechanical 
therapy offers endoscopic clips and band ligation. Thermal 
devices deliver electrical current (through direct contact 
or via an inert gas plasma) or heat to the target tissue. 
Moreover, a few new technologies have emerged, such 
as hemostatic powders. 
INJECTION TREATMENT
Injection needles consist of an outer sheath (plastic, 
Teflon, or stainless steel) and an inner hollow-core 
needle (19-25 gauge)[14]. Using a handle on the end of 
the needle sheath, the operator can retract the needle 
into the sheath for safe passage through the working 
channel of the endoscope. When the catheter is placed 
near the target tissue, the needle is extended a preset 
distance out of the end of the sheath, and a syringe 
attached to the handle is used to inject liquid agents 
into the target tissue. Dilute epinephrine in saline 
(1:10000) is applied with an injection needle in 0.5-1.0 
mL boluses to the four quadrants around the high-risk 
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Table 2  Complete rockall risk scoring system for assessment after an episode of acute upper gastrointestinal bleeding[12]
Variables Score 0 Score 1 Score 2 Score 3
Age Younger than 60 yr 60-79 yr 80 yr or older -
Shock symptoms, systolic 
blood pressure, heart rate
Shock absent, blood pressure 100 
mmHg or greater, heart rate 100 
bpm or greater
Tachycardia, blood pressure 
100 mmHg or greater, heart 
rate 100 bpm or greater
Hypotension, blood pressure 
less than 100 mmHg
-
Comorbidities No major comorbidity - Heart failure, coronary artery 
disease, any major comorbidity
Renal failure, liver failure, 
disseminated malignancy
Endoscopic diagnosis Mallory-Weiss tear or no lesion 
identified, and no stigmata of recent 
hemorrhage
All other diagnoses Malignancy of upper GI tract -
Stigmata of recent 
hemorrhage
Low-risk - High-risk -
Low-risk stigmata of bleeding: Clean base ulcer, pigmented spots; High-risk stigmata of bleeding: Adherent clot, visible or spurting vessel, active bleeding; 
Bpm: Beats per minute; GI: Gastrointestinal.
Table 3  Recommendations of the american society for gastrointestinal endoscopy concerning upper gastrointestinal bleeding 
management[38]
We recommend that patients with UGIB be adequately resuscitated before endoscopy
We recommend antisecretory therapy with PPIs for patients with bleeding caused by peptic ulcers or in those with suspected peptic ulcer bleeding 
awaiting endoscopy
We suggest prokinetic agents in patients with a high probability of having fresh blood or a clot in the stomach when undergoing endoscopy
We recommend endoscopy to diagnose the etiology of acute UGIB. The timing of endoscopy should depend on clinical factors. Urgent endoscopy (within 
24 h of presentation) is recommended for patients with a history of malignancy or cirrhosis, presentation with hematemesis, and signs of hypovolemia 
including hypotension, tachycardia and shock, and a hemoglobin < 8 g/dL
We recommend endoscopic therapy for peptic ulcers with high-risk stigmata (active spurting, visible vessel). The management of PUD with an adherent 
clot is controversial. Recommended endoscopic treatment modalities include injection (sclerosants, thrombin, fibrin, or cyanoacrylate glue), cautery, and 
mechanical therapies
We recommend against epinephrine injection alone for peptic ulcer bleeding. If epinephrine injection is performed, it should be combined with a second 
endoscopic treatment modality (e.g. , cautery or clips)
We recommend that patients with low-risk lesions be considered for outpatient management
We recommend against routine second-look endoscopy in patients who have received adequate endoscopic therapy
We recommend repeat endoscopy for patients with evidence of recurrent bleeding
UGIB: Upper gastrointestinal bleeding; PPIs: Proton pump inhibitors; PUD: Peptic ulcer disease.
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causes physical tamponade at a bleeding site[15]. It 
includes endoscopic clips and band ligation (Figures 
1 and 2). Metal clips are particularly useful for small 
bleeding ulcers (i.e., Dieulafoy lesions), for Mallory-
Weiss tears, and for large, visible vessels. Endoscopic 
clips are deployed over a bleeding site (e.g., visible 
vessel) and typically slough off within days to weeks 
after placement. Endoscopic clips function by mechanical 
compression of the bleeding vessel and theoretically 
cause less tissue injury than cautery methods. Band 
ligation is widely used in variceal bleeding. However, it 
has also been found to be effective in treating bleeding 
Dieulafoy’s lesions[23].
The Over-The-Scope Clip (OTSC; Ovesco, Tübingen, 
Germany) is a modern endoscopic clipping device de-
signed for tissue approximation. It has been used for 
the closure of fistulas and perforations. OTSC consists 
of a nitinol clip mounted on an applicator cap that is 
affixed to the tip of the endoscope. The deployed clip 
captures and closes tissue suctioned into the applicator 
cap, thus compressing the lesions until healing. Studies 
on animal models and limited data from clinical use 
support the efficacy of OTSC for the treatment of GI 
bleeding, and a number of small case series have shown 
effective hemostasis resulting from the use of OTSC in 
patients for whom epinephrine injection or standard clip 
placement failed[24]. The OTSC is now available on the 
market and gives the physician a tool for the immediate 
management of complications, such as deep-wall 
lesions, difficult bleeding or perforations.
THERMAL THERAPY
Thermal therapies include electrocautery probes 
(monopolar, bipolar or multipolar) and heater probes, 
which are referred to as contact thermal modalities, and 
argon plasma coagulation (APC) and laser phototherapy, 
which are known as noncontact techniques. Bipolar 
and multipolar probes provide constant bipolar elec-
trocoagulation, which is assumed to be safer than 
monopolar diathermy (which produces an unpredictable 
depth of damage and a higher risk of perforation). A foot 
pedal controls the delivery of energy. The power output 
is in watts (W). Maximum power settings are dependent 
stigmata or to the base of the active bleeding site and 
then in the middle of it, up to a total of 10 mL[15,16]. 
Some practitioners prefer to use absolute alcohol in 
much smaller volumes (1-2 mL in 0.1 mL aliquots) or 
combinations of epinephrine and alcohol or sclerosants, 
which are used for the treatment of varices. Epinephrine 
injection therapy promotes initial hemostasis through 
a combination of vasoconstriction, compression (local 
tamponade), and platelet activation, but this effect 
declines after 20 min. If epinephrine injection is per-
formed, it should usually be combined with a second 
endoscopic treatment modality (e.g., electrocautery 
or clips)[17]. If epinephrine is used alone, there is a 
significant risk of rebleeding. This can be reduced by 
injecting large volumes, as high as 30 mL, which are 
associated with no clearly described cardiologic adverse 
events, and the rebleeding rate decreases linearly with 
the injected volume[18,19]. Dilute epinephrine injection 
is inferior at preventing rebleeding and surgery when 
compared with bipolar electrocoagulation, clips, or fibrin 
glue[20]. Other injected substances, such as sclerosing 
agents (e.g., polidocanol, ethanolamine, and ethanol), 
have similar efficacy but more side effects, including 
transmural necrosis or perforation[21]. Another class 
of injectable agents are tissue adhesives, including 
cyanoacrylate glues, thrombin and fibrin, which are 
used to create a primary seal at the site of bleeding 
by inducing thrombosis through direct tissue injury. 
However, they may also evoke tissue necrosis and, 
hence, the limit for injected volumes is less than 1 mL. 
Cyanoacrylate (n-butyl-2-cyanoacrylate, Histoacryl; 
Braun, Germany) is a liquid tissue adhesive that consists 
of monomers that rapidly polymerize (creating long and 
strong chains) in an exothermic reaction after contact 
with hydroxide ions[22]. Cyanoacrylate is widely used for 
the management of bleeding esophageal and gastric 
varices, but it is not recommended for acute non-variceal 
upper gastrointestinal bleeding. However, in difficult-
to-arrest non-variceal bleeding, it could be a useful and 
safe therapeutic tool.
MECHANICAL THERAPY
Mechanical therapy refers to the use of a device that 
Figure 2  Endoscopic band ligation.
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Figure 1  Endoscopic clips.
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on the generator used but usually do not exceed 50 W. 
A standard setting is 20 W.
A heater probe provides constant heat at 250 ℃, 
which is released by a diode in the probe tip and directly 
transferred to tissue to affect coagulation. Contact 
treatment devices share some common principles. All 
can be applied tangentially but are better used face-
on, if possible. When the vessel is actively bleeding, 
direct probe pressure on the vessel or feeding vessel 
will reduce the flow and increase the effectiveness of 
treatment. Mechanically pressuring the probe tip directly 
to the bleeding site, combined with heat or electrical 
current to coagulate blood vessels, is a process known 
as “captive coagulation”. The bipolar and heater probes 
incorporate a flushing water jet, which helps to prevent 
sticking. 
Argon plasma coagulation, which is performed 
without tissue contact, uses the electrical conductivity 
of argon gas (Figure 3). The argon, passed down an 
electrode catheter and energized via an intelligent-
circuitry electrosurgical unit and patient plate, ionizes to 
produce a local plasma arc. The produced heating effect 
is inherently superficial (2-3 mm at most, unless the 
current is applied in the same place for many seconds). 
Therefore, APC is used to treat superficial mucosal 
lesions, such as vascular malformations and gastric 
antral vascular ectasias. The APC probe should be 
positioned 2-10 mm from the lesion and the argon gas 
flow should be 1.5-2 L/min at a power of 40-50 W[25,26].
Laser phototherapy uses an Nd:YAG laser to create 
hemostasis by generating heat to induce direct vessel 
coagulation. This is a noncontact thermal method. It is 
not as effective as captive coagulation because it lacks 
the use of compression to create a tamponade effect[27]. 
An additional deterrent to its use is expense.
To perform laser coagulation, the area near the 
vessel is first injected with epinephrine to reduce blood 
flow (reducing the heat-sink effect). Then, the laser is 
applied around the vessel, producing a wall of edema. 
Caution must be taken to avoid drilling into the vessel 
with the laser, which can cause increased bleeding.
TOPICAL HEMOSTATIC AGENTS
Topical hemostatic agents are new tools used in 
endoscopic hemostasis. Three different powders are 
available: Hemospray (Cook Medical, Winston-Salem, 
NC, United States), Ankaferd BloodStopper, and 
EndoClot (EndoClot Plus Inc., Santa Clara, CA, United 
States)[28]. 
Hemospray (TC-325), a novel proprietary inorganic 
powder, has recently been approved in Canada for the 
management of NVUGIB[29]. The powder is administered 
through a 10- or 7-French catheter via a CO2-pressurised 
canister. It achieves hemostasis by adhering to the 
bleeding site, leading to mechanical tamponade and, by 
concentrating and activating platelets and coagulation 
factors, promoting thrombus formation. Its ability to 
cover large areas with multiple bleeding points makes 
it a suitable choice for hemorrhagic gastritis, gastric 
antral vascular ectasia, radiation-induced mucosal injury 
and malignancy-related bleeding[29]. Other advantages 
include ease of use, the lack of need for precise lesion 
targeting and access to lesions in difficult locations. 
Hemostatic sprays derived from plants have also 
been invented. Clinical use of these agents for endo-
scopic hemostasis is currently limited to the off-label 
use of ankaferd blood stopper (ABS) (Ankaferd Health 
Products Ltd., Istanbul, Turkey), a mixture of extracts 
from several plants that is approved in Turkey for the 
topical treatment of dental and postsurgical external 
bleeding. ABS is delivered through the working channel 
of the scope using a spray catheter.
The EndoClot Polysaccharide Hemostatic System 
(EndoClot Plus Inc., Santa Clara, CA, United States) 
is the latest available hemostatic powder. It consists 
of starch, which explains its availability in European 
countries, Australia, Malaysia, and Turkey, despite a 
lack of rigorous scientific evidence for its efficacy. The 
effectiveness of the powder at controlling and preventing 
bleeding related to endoscopic mucosal resection has 
been recently described[28].
PRE-ENDOSCOPY PHARMACOLOGIC 
THERAPY
Prokinetic agents, such as intravenously administered 
erythromycin or metoclopramide, should be considered 
for use 30 min prior to endoscopy to improve visibility[30]. 
Intravenous prokinetic agents, when administered 20 
to 120 min before endoscopy in patients with acute 
UGIB, decrease the need for a repeat endoscopy to 
determine the site and cause of bleeding. However, their 
use has not demonstrated any benefit to other clinical 
parameters, such as transfusion requirement, length of 
hospital stay, or need for surgery.
Proton pump inhibitor (PPI) therapy is another 
pharmacologic intervention that should be considered 
in patients suspected to have UGIB (e.g., pantoprazole 
80 mg bolus followed by 8 mg/h continuous drip or 
40 mg intravenously every 12 h). The infusion is con-
tinued for 48-72 h. The relative efficacy of PPIs may 
be due to their superior ability to maintain gastric pH 
at a level above 6.0, thereby protecting ulcer clots 
Szura M et al . Endoscopic methods of hemostasis
Figure 3  Argon plasma coagulation.
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from fibrinolysis. Multiple analyses have shown that 
applying PPI therapy before a procedure significantly 
reduced the rate of high-risk stigmata that are identified 
by endoscopy and the need for endoscopic therapy. 
Therefore, intravenous PPI therapy is recommended for 
patients who are suspected of having acute NVUGIB.
EFFICACY AND COMPARATIVE 
ANALYSIS 
Gastroduodenal peptic ulcers are by far the most 
common etiology of UGIB, accounting for 50% of 
admissions among patients with upper gastrointestinal 
hemorrhage[28]. Multiple meta-analyses evaluating 
endoscopic therapies for bleeding peptic ulcers have 
demonstrated that thermal devices, injectable agents 
other than epinephrine (i.e., sclerosants and thrombin/
fibrin glue), and clips were all effective methods for 
achieving hemostasis in PUD, with no single modality 
being superior to the others. In particular, hemoclip 
placement, thermocoagulation (e.g., heater probe), 
and electrocoagulation (e.g., Gold probe, BICAP probe) 
all seem to be equivalent alternatives[20,31-34]. Dual 
combination therapy (i.e., epinephrine injection plus other 
injections or thermal or mechanical methods) was proven 
to be significantly superior to epinephrine injection alone, 
but displays no advantage over thermal or mechanical 
monotherapy. This means that epinephrine should no 
longer be applied as a monotherapy for treating lesions 
with high-risk stigmata and should only be used in 
combination with other methods as these combinations 
significantly reduce the risk of rebleeding and surgery. 
Prospective randomized trials have demonstrated 
that thermal therapy results in significant reductions 
in bleeding, blood transfusions, length of hospital 
stays, and the need for urgent surgery in patients with 
actively bleeding ulcers or nonbleeding ulcers with 
visible vessels[35]. A meta-analysis of randomized trials 
that evaluated rebleeding rates following injection, 
thermal therapy, clips, or combination therapy showed 
that clips were superior to thermal therapy[33]. The 
remaining causes of UGIB account for up to 50% of 
cases. For gastric antral vascular ectasia (GAVE), APC 
remains the most commonly reported modality that is 
usually performed over multiple endoscopic sessions. 
APC is associated with a decrease in transfusion 
requirements[36]. Mallory-Weiss tear bleeding usually 
spontaneously stops, with the rates of rebleeding from 
this etiology reaching up to 10%. Patients with active 
bleeding or oozing require endoscopic therapy. Bipolar 
electrocoagulation, epinephrine injection, clips, and band 
ligation have all been used successfully with no difference 
in immediate hemostasis or rebleeding. Endoscopic 
therapy is the first choice in bleeding Dieulafoy’s lesions 
and is usually performed via clipping or banding of the 
lesion[23]. Endoscopic clipping is superior to endoscopic 
injection and is comparable to thermocoagulation in 
securing hemostasis in bleeding peptic ulcers and 
Dieulafoy’s lesions[28]. Endoscopic hemostasis of bleeding 
upper GI tract tumors has proven to be less effective and 
to have higher rates of rebleeding. Various endoscopic 
treatment modalities have been described with no 
clear recommendations. Several studies have reported 
that cyanoacrylate was used for acute non-variceal 
gastrointestinal bleeding cessation[21]. Application of 
cyanoacrylate (by injection and/or spraying) is a safe and 
effective method for achieving immediate hemostasis 
when conventional endoscopic treatment has been 
unsuccessful. This technique is easy to perform and 
should be considered in cases of patients with difficult-to-
arrest acute NVGIB. Recently, promising preliminary data 
have been reported following the use of the hemostatic 
powder TC-325 (Hemospray) for bleeding control from 
upper GI tract tumors[37].
CONCLUSION
Endoscopy is the mainstay for the modern management 
of NVUGIB. Ideally, endoscopy should be performed 
within 24 h of presentation, after adequate resuscitation 
has been performed. Many safe and effective devices 
are available for endoscopic hemostasis. Combination 
therapy using the injection of epinephrine plus another 
hemostatic technique is more effective than epinephrine 
alone. Hemospray is a new and promising endoscopic 
therapy. Patients with high-risk stigmata should receive 
continuous intravenous PPI administration for 72 h 
after endoscopy. After the acute phase, the underlying 
cause of the lesion should be verified and treated, when 
possible. The choice of therapy should remain at the 
discretion of the physician, based on the nature and 
position of the lesion, the availability and experience of 
the endoscopist and the previous endoscopic therapy 
that the patient has received.
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